Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27527586 | 0.95 | LIPG (0.41) | LIPGRECQLNR1H2NR1H3 | |
| Cyanide SCHEMBL27388351 | 0.91 | LIPG (0.39) | LIPGRECQLNR1H2NR1H3 | |
| SCHEMBL10690933 | 0.81 | GABRA1 (0.30) | GABRA1GABRB2 | |
| SCHEMBL10694395 | 0.81 | TDP1 (0.31) | GABRA1GABRB2TDP1 | |
| SCHEMBL10181651 | 0.78 | LIPG (0.43) | CYP3A4CYP2D6CYP2C9LIPGCTSB | |
| SCHEMBL10383754 | 0.77 | HSD11B1 (0.31) | — | |
| SCHEMBL8549823 | 0.77 | GABRA1 (0.32) | GABRA1GABRB2CTSB | |
| SCHEMBL10646473 | 0.77 | GABRA1 (0.35) | GABRA1GABRB2CTSB | |
| SCHEMBL8932920 | 0.76 | LIPG (0.42) | CYP3A4CYP2D6CYP2C9LIPGCTSB | |
| SCHEMBL12004765 | 0.76 | PSIP1 (0.42) | CYP3A4CYP2D6CYP2C9LIPGCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | LECTUS THERAPEUTICS LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | LECTUS THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | KCNH3, KCNN3, KCNH2 | CYP3A4 766/4885CYP2D6 412/4885CYP2C9 368/4885 |
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | HCAR2, HCAR1, SCN7A | CYP3A4 670/4885CYP2D6 330/4885CYP2C9 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.